RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.
TCGA (cancer tissue):
Expressed in all
HPA (cell line):
Expressed in all
HPA (normal tissue):
Expressed in all
Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.
Evidence at protein level
Protein expression normal tissuei
A summary of the overall protein expression pattern across the analyzed normal tissues. The summary is based on knowledge-based annotation.
"Estimation of protein expression could not be performed. View primary data." is shown for genes analyzed with a knowledge-based approach where available RNA-seq and gene/protein characterization data has been evaluated as not sufficient in combination with immunohistochemistry data to yield a reliable estimation of the protein expression profile.
Cytoplasmic and nuclear expression in most tissues.
IMMUNOHISTOCHEMISTRY DATA RELIABILITY
Data reliability descriptioni
Standardized explanatory sentences with additional information required for full understanding of the knowledge-based expression profile.
Antibody staining mainly consistent with RNA expression data.
Reliability score - normal tissuesi
Reliability score (score description), divided into Enhanced, Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between antibody staining pattern, available RNA-Seq and gene/protein characterization data, as well as similarity between independent antibodies targeting the same protein.
Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.
Gene product is not prognostic.
RNA EXPRESSION OVERVIEWi
RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name. The cancer types are color-coded according to which type of normal organ the cancer originates from.
Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
For each cancer, color-coded bars indicate the percentage of patients (maximum 12 patients) with high and medium protein expression level. The cancer types are color-coded according to which type of normal organ the cancer originates from. Low or not detected protein expression results in a white bar. Mouse-over function shows details about expression level and normal tissue of origin. The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle between the different antibodies.
Malignant cells generally displayed moderate to strong cytoplasmic and nuclear immunoreactivity.
Weak to moderate cytoplasmic staining in all malignant tissues.
Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.
PARK7 (HGNC Symbol)
Parkinsonism associated deglycase (HGNC Symbol)
Entrez gene summary
The product of this gene belongs to the peptidase C56 family of proteins. It acts as a positive regulator of androgen receptor-dependent transcription. It may also function as a redox-sensitive chaperone, as a sensor for oxidative stress, and it apparently protects neurons against oxidative stress and cell death. Defects in this gene are the cause of autosomal recessive early-onset Parkinson disease 7. Two transcript variants encoding the same protein have been identified for this gene. [provided by RefSeq, Jul 2008]
The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.
At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.
Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50). The region with the lowest possible identity is always selected for antigen design, with a maximum identity of 60% allowed for designing a single-target antigen (read more).
The curve in blue displays the predicted antigenicity i.e. the tendency for different regions of the protein to generate an immune response, with peak regions being predicted to be more antigenic.The curve shows average values based on a sliding window approach using an in-house propensity scale. (read more).
If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.
Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.
The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.
The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.
The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.
The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.
Q99497 [Direct mapping] Protein deglycase DJ-1 V9HWC2 [Target identity:100%; Query identity:100%] Epididymis secretory sperm binding protein Li 67p
Enzymes ENZYME proteins Hydrolases Peptidases Cysteine-type peptidases SPOCTOPUS predicted membrane proteins Predicted intracellular proteins Plasma proteins Disease related genes Potential drug targets Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)
GO:0000785 [chromatin] GO:0001933 [negative regulation of protein phosphorylation] GO:0002866 [positive regulation of acute inflammatory response to antigenic stimulus] GO:0003713 [transcription coactivator activity] GO:0003723 [RNA binding] GO:0003729 [mRNA binding] GO:0005102 [receptor binding] GO:0005507 [copper ion binding] GO:0005515 [protein binding] GO:0005634 [nucleus] GO:0005737 [cytoplasm] GO:0005739 [mitochondrion] GO:0005747 [mitochondrial respiratory chain complex I] GO:0005829 [cytosol] GO:0005886 [plasma membrane] GO:0005913 [cell-cell adherens junction] GO:0006469 [negative regulation of protein kinase activity] GO:0006508 [proteolysis] GO:0006517 [protein deglycosylation] GO:0006914 [autophagy] GO:0006954 [inflammatory response] GO:0007005 [mitochondrion organization] GO:0007265 [Ras protein signal transduction] GO:0007338 [single fertilization] GO:0008134 [transcription factor binding] GO:0008233 [peptidase activity] GO:0009438 [methylglyoxal metabolic process] GO:0010273 [detoxification of copper ion] GO:0010628 [positive regulation of gene expression] GO:0010629 [negative regulation of gene expression] GO:0016020 [membrane] GO:0016532 [superoxide dismutase copper chaperone activity] GO:0016605 [PML body] GO:0016684 [oxidoreductase activity, acting on peroxide as acceptor] GO:0016787 [hydrolase activity] GO:0019249 [lactate biosynthetic process] GO:0019899 [enzyme binding] GO:0019900 [kinase binding] GO:0019955 [cytokine binding] GO:0030424 [axon] GO:0031397 [negative regulation of protein ubiquitination] GO:0032091 [negative regulation of protein binding] GO:0032148 [activation of protein kinase B activity] GO:0032435 [negative regulation of proteasomal ubiquitin-dependent protein catabolic process] GO:0032757 [positive regulation of interleukin-8 production] GO:0033138 [positive regulation of peptidyl-serine phosphorylation] GO:0033234 [negative regulation of protein sumoylation] GO:0033864 [positive regulation of NAD(P)H oxidase activity] GO:0034599 [cellular response to oxidative stress] GO:0036470 [tyrosine 3-monooxygenase activator activity] GO:0036471 [cellular response to glyoxal] GO:0036478 [L-dopa decarboxylase activator activity] GO:0036524 [protein deglycase activity] GO:0036525 [protein deglycation] GO:0036526 [peptidyl-cysteine deglycation] GO:0036527 [peptidyl-arginine deglycation] GO:0036528 [peptidyl-lysine deglycation] GO:0036529 [protein deglycation, glyoxal removal] GO:0036530 [protein deglycation, methylglyoxal removal] GO:0036531 [glutathione deglycation] GO:0042743 [hydrogen peroxide metabolic process] GO:0042802 [identical protein binding] GO:0042803 [protein homodimerization activity] GO:0043066 [negative regulation of apoptotic process] GO:0043523 [regulation of neuron apoptotic process] GO:0043524 [negative regulation of neuron apoptotic process] GO:0044388 [small protein activating enzyme binding] GO:0044390 [ubiquitin-like protein conjugating enzyme binding] GO:0045121 [membrane raft] GO:0045296 [cadherin binding] GO:0045340 [mercury ion binding] GO:0045944 [positive regulation of transcription from RNA polymerase II promoter] GO:0046295 [glycolate biosynthetic process] GO:0046826 [negative regulation of protein export from nucleus] GO:0048471 [perinuclear region of cytoplasm] GO:0050681 [androgen receptor binding] GO:0050727 [regulation of inflammatory response] GO:0050787 [detoxification of mercury ion] GO:0050821 [protein stabilization] GO:0051091 [positive regulation of sequence-specific DNA binding transcription factor activity] GO:0051444 [negative regulation of ubiquitin-protein transferase activity] GO:0051881 [regulation of mitochondrial membrane potential] GO:0051897 [positive regulation of protein kinase B signaling] GO:0060548 [negative regulation of cell death] GO:0060765 [regulation of androgen receptor signaling pathway] GO:0070062 [extracellular exosome] GO:0070301 [cellular response to hydrogen peroxide] GO:0070491 [repressing transcription factor binding] GO:0090073 [positive regulation of protein homodimerization activity] GO:0097110 [scaffold protein binding] GO:0098793 [presynapse] GO:0098869 [cellular oxidant detoxification] GO:1900182 [positive regulation of protein localization to nucleus] GO:1901215 [negative regulation of neuron death] GO:1901671 [positive regulation of superoxide dismutase activity] GO:1901984 [negative regulation of protein acetylation] GO:1902236 [negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway] GO:1902903 [regulation of supramolecular fiber organization] GO:1902958 [positive regulation of mitochondrial electron transport, NADH to ubiquinone] GO:1903073 [negative regulation of death-inducing signaling complex assembly] GO:1903094 [negative regulation of protein K48-linked deubiquitination] GO:1903122 [negative regulation of TRAIL-activated apoptotic signaling pathway] GO:1903135 [cupric ion binding] GO:1903136 [cuprous ion binding] GO:1903168 [positive regulation of pyrroline-5-carboxylate reductase activity] GO:1903178 [positive regulation of tyrosine 3-monooxygenase activity] GO:1903181 [positive regulation of dopamine biosynthetic process] GO:1903189 [glyoxal metabolic process] GO:1903197 [positive regulation of L-dopa biosynthetic process] GO:1903200 [positive regulation of L-dopa decarboxylase activity] GO:1903202 [negative regulation of oxidative stress-induced cell death] GO:1903206 [negative regulation of hydrogen peroxide-induced cell death] GO:1903208 [negative regulation of hydrogen peroxide-induced neuron death] GO:1903377 [negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway] GO:1903384 [negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway] GO:1903599 [positive regulation of mitophagy] GO:1905259 [negative regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway] GO:1990381 [ubiquitin-specific protease binding] GO:2000157 [negative regulation of ubiquitin-specific protease activity] GO:2000679 [positive regulation of transcription regulatory region DNA binding] GO:2000825 [positive regulation of androgen receptor activity] GO:2001237 [negative regulation of extrinsic apoptotic signaling pathway] GO:2001268 [negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway]